Zydus Cadila gets USFDA nod for multiple sclerosis treatment drug

Topics Zydus Cadila | USFDA

Representative image

Drug firm Zydus Cadila on Friday said it has received final approval from the US health regulator to market Dimethyl Fumarate delayed release capsules, indicated for the treatment of patients with relapsing forms of multiple sclerosis.

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed release capsules, (Tecfidera)in the strengths of 120 mg and 240 mg, Zydus Cadila, part of Cadila Healthcare group, said in a regulatory filing.

Zydus Cadila said in its approval, the USFDA noted that Zydus was one of the first abbreviated new drug application applicants to submit a substantially complete ANDA and is, therefore, eligible for 180 days of generic drug exclusivity along with other first ANDA applicants.

"The USFDA granted approval following entry of judgment in favour of Zydus Cadila and other ANDA applicants by the United States District Court for the District of Delaware, holding that the only unexpired patent covering Tecfidera is invalid," the company added.

Zydus Cadilasaid the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Matoda.

The group now has 303 approvals and has so far filed over 390 abbreviated new drug applications since the commencement of the filing process in 2003-04.

Cipla on Friday said it has also received final approval from the USFDA forDimethyl Fumarate capsules.

Quoting IQVIA (IMS Health) data, Cipla said Tecfidera had US sales of approximately USD 3.8 billion for the 12-month period ending July 2020.

Shares of Cadila Healthcare were trading 0.39per cent lower at Rs 377.50 apiece on BSE.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel